These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25277167)

  • 1. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
    Cozzolino M; Messa P; Brancaccio D; Cannella G; Bolasco P; Di Luca M; Costanzo AM; Paparatti Ud; Festa V; Gualberti G; Mazzaferro S;
    Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
    CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
    Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
    Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
    Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Wei M; Taskapan H; Esbaei K; Jassal SV; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2006; 38(3-4):739-43. PubMed ID: 17160632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
    Al Aly Z; González EA; Martin KJ; Gellens ME
    Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study.
    Janjua TK; Mukhtar KN; Naveed AK; Ahmed EB; Rehan M
    Pan Afr Med J; 2019; 33():183. PubMed ID: 31565143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.